Sign in

You're signed outSign in or to get full access.

Heidi Jacobson

Research Analyst at Leerink Partners

Heidi Jacobson is an Equity Research Associate at Leerink Partners, specializing in healthcare and life sciences with a focus on emerging immunology. She contributes to coverage in sectors including emerging immunology, diversified biopharmaceuticals, and neuroscience, supporting analysts on companies such as those listed under Faisal A. Khurshid in emerging immunology, though specific company names directly attributed to her are not detailed in public coverage lists. Jacobson brings sector knowledge to Leerink Partners' investment banking research team, with her role confirmed across recent firm documents, but detailed performance metrics, career timeline, previous experience, and professional credentials like FINRA registrations are not publicly available in accessible sources.

Heidi Jacobson's questions to Ascendis Pharma (ASND) leadership

Question · Q4 2025

Heidi Jacobson asked how the TransCon CNP launch, including launch investment and early revenue contribution, is factored into Ascendis Pharma's EUR 500 million operating cash flow target for 2026.

Answer

Jan Møller Mikkelsen, President and Chief Executive Officer, clarified that the TransCon CNP launch is not incorporated into the current EUR 500 million operating cash flow target for 2026. He stated that Ascendis Pharma will provide updated guidance once initial uptake, expected to be high in the U.S. and internationally, is observed.

Ask follow-up questions

Fintool

Fintool can predict Ascendis Pharma logo ASND's earnings beat/miss a week before the call